Exploring the relationship between intestinal microbiota and immune checkpoint inhibitors in the treatment of non-small cell lung cancer: insights from the "lung and large intestine stand in exterior-interior relationship" theory

被引:0
|
作者
Li, Luwei [1 ,2 ]
Zhong, Hongmei [1 ,2 ]
Wang, Yajie [1 ,2 ]
Pan, Zongying [1 ,2 ]
Xu, Shumei [1 ,2 ]
Li, Shuai [1 ,2 ]
Zeng, Guilin [2 ]
Zhang, Weiwei [2 ]
Li, Jie [3 ]
He, Lang [2 ]
机构
[1] Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan, Peoples R China
[2] Chengdu Univ Tradit Chinese Med, Chengdu Peoples Hosp 5, Canc Prevent & Treatment Inst Chengdu, Dept Oncol,Clin Med Coll 2,Affiliated Peoples Hosp, Chengdu, Peoples R China
[3] Chengdu Fifth Peoples Hosp, Ctr Med Res & Translat, Chengdu, Peoples R China
来源
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY | 2024年 / 14卷
关键词
biomarkers of intestinal flora; immunotherapy; non-small cell lung cancer; TCM syndrome type; immune microenvironment; lung and large intestine; INVASIVE PULMONARY ADENOCARCINOMA; INTERNATIONAL ASSOCIATION; GUT MICROBIOME; GRADING SYSTEM; DYSBIOSIS; EPIDEMIOLOGY; EFFICACY;
D O I
10.3389/fcimb.2024.1341032
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective This study is aim to discern the Traditional Chinese Medicine (TCM) syndrome classifications relevant to immunotherapy sensitive in non-small cell lung cancer (NSCLC) patients, and to delineate intestinal microbiota biomarkers and impact that wield influence over the efficacy of NSCLC immunotherapy, grounded in the TCM theory of "lung and large intestine stand in exterior-interior relationship."Methods The study cohort consisted of patients with advanced NSCLC who received treatment at the Oncology Department of Chengdu Fifth People's Hospital. These patients were categorized into distinct TCM syndrome types and subsequently administered immune checkpoint inhibitors (ICIs), specifically PD-1 inhibitors. Stool specimens were collected from patients both prior to and following treatment. To scrutinize the differences in microbial gene sequences and species of the intestinal microbiota, 16S rRNA amplicon sequencing technology was employed. Additionally, peripheral blood samples were collected, and the analysis encompassed the assessment of T lymphocyte subsets and myeloid suppressor cell subsets via flow cytometry. Subsequently, alterations in the immune microenvironment pre- and post-treatment were thoroughly analyzed.Results The predominant clinical manifestations of advanced NSCLC patients encompassed spleen-lung Qi deficiency syndrome and Qi-Yin deficiency syndrome. Notably, the latter exhibited enhanced responsiveness to ICIs with a discernible amelioration of the immune microenvironment. Following ICIs treatment, significant variations in microbial abundance were identified among the three strains: Clostridia, Lachnospiraceae, and Lachnospirales, with a mutual dependency relationship. In the subset of patients manifesting positive PD-L1 expression and enduring therapeutic benefits, the study recorded marked increases in the ratios of CD3+%, CD4+%, and CD4+/CD8+ within the T lymphocyte subsets. Conversely, reductions were observed in the ratios of CD8%, Treg/CD4+, M-MDSC/MDSC, and G-MDSC/MDSC.Conclusion The strains Clostridia, Lachnospiraceae, and Lachnospirales emerge as potential biomarkers denoting the composition of the intestinal microbiota in the NSCLC therapy. The immunotherapy efficacy of ICIs markedly accentuates in patients displaying durable treatment benefits and those expressing positive PD-L1.
引用
收藏
页数:22
相关论文
共 50 条
  • [21] Immune Checkpoint Inhibitors in Oncogenic Driven Non-small Cell Lung Cancer
    Fonseca, A.
    Silva, E.
    Coutinho, D.
    Campainha, S.
    Dias, M.
    Barroso, A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S339 - S340
  • [22] Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
    Qiu, Zhenbin
    Chen, Zihao
    Zhang, Chao
    Zhong, Wenzhao
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2019, 8 (01)
  • [23] Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Ushio, Ryota
    Murakami, Shuji
    Saito, Haruhiro
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (07)
  • [24] Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Jung, Chi Young
    Antonia, Scott J.
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2018, 81 (01) : 29 - 41
  • [25] Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer
    Lin, Gen
    Wang, Zhijie
    Chu, Qian
    Hu, Yi
    Huang, Dingzhi
    Wang, Jun
    Yang, Fan
    Zhong, Wenzhao
    Zhou, Chengzhi
    Zhu, Bo
    Ai, Xinghao
    Cao, Baoshan
    Cao, Yabing
    Chen, Mingqiu
    Chen, Xiaohui
    Chu, Tianqing
    Duan, Jianchun
    Fan, Yun
    Fang, Yong
    Feng, Shuitu
    Feng, Weineng
    Guo, Hui
    Han, Chengbo
    He, Yong
    Hong, Shaodong
    Hu, Jie
    Huang, Meijuan
    Huang, Yan
    Jiang, Da
    Jiang, Kan
    Jiang, Richeng
    Jin, Bo
    Jin, Shi
    Li, Jisheng
    Li, Min
    Li, Ziming
    Li, Chao
    Lin, Jie
    Liu, Anwen
    Liu, Si-Yang Maggie
    Yutao, Liu
    Liu, Zhefeng
    Liu, Zhe
    Liu, Zhenhua
    Liu, Zhentian
    Liu, Zhigang
    Lu, Yuping
    Lv, Tangfeng
    Ma, Zhiyong
    Miao, Qian
    THORACIC CANCER, 2024, 15 (05) : 419 - 426
  • [26] Chronological Effects of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Guo, Xinyue
    Qin, Lanqun
    Wang, Xinmeng
    Geng, Qian
    Li, Dongqing
    Lu, Yingying
    Jiang, Hua
    IMMUNOLOGY, 2025, 174 (04) : 402 - 410
  • [27] The role of immune checkpoint inhibitors in advanced non-small cell lung cancer
    Pistamaltzian, Nikolaos F.
    Georgoulias, Vassilis
    Kotsakis, Athanasios
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2019, 13 (05) : 435 - 447
  • [28] Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer
    Miura, Yosuke
    Kasahara, Norimitsu
    Sunaga, Noriaki
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S628 - S632
  • [29] Safety of current immune checkpoint inhibitors in non-small cell lung cancer
    Abdayem, Pamela
    Planchard, David
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (06) : 651 - 667
  • [30] Immune checkpoint inhibitors in therapy of non-small cell lung cancer (a review)
    Kolesnik, O. P.
    Mykhailychenko, V. V.
    ZAPOROZHYE MEDICAL JOURNAL, 2021, 23 (03) : 418 - 425